William Nichols, MD
Interventional Cardiology · Jackson, MSNPI 1306258330
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $17,065 of the $25,156 with a category attached, or 67.8%. 34 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 37.7% of the total. Reporting peaked in 2022 at $11,494 and has fallen 91.8% since, to $944 in 2025.
Across 377 payments — averaging $66.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$9K
- Medtronic$9K
- Abbott$3K
- Novartis$1K
- Pfizer$513
- Boston Scientific$479
- plus $2K from 28 others
What the payments were for
- Travel & lodging$17,06568%
- Food & beverage$8,01232%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 16 | $9,480 |
| Medtronic | 93 | $8,663 |
| Abbott | 29 | $2,503 |
| Novartis | 78 | $1,021 |
| Pfizer | 35 | $513 |
| Boston Scientific | 11 | $479 |
| Boehringer Ingelheim | 23 | $473 |
| Edwards Lifesciences | 4 | $330 |
| Amgen | 16 | $238 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $194 |
| E.r. Squibb & Sons, L.L.C. | 12 | $167 |
| Livanova USA, Inc. | 1 | $120 |
| Actelion Pharmaceuticals US, Inc. | 4 | $118 |
| AstraZeneca | 8 | $106 |
| Stryker | 4 | $91 |
| Angiodynamics, Inc. | 1 | $88 |
| Astellas Pharma US Inc | 4 | $80 |
| Johnson & Johnson | 6 | $77 |
| Novo Nordisk | 4 | $65 |
| Bayer | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Lexicon Pharmaceuticals, Inc. | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Silk Road Medical, Inc. | 1 | $27 |
| Cardiva Medical, Inc. | 1 | $25 |
| Inari Medical, Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Gilead | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Penumbra, Inc. | 1 | $17 |
| Eagle Pharmaceuticals, Inc. | 1 | $15 |
| Zimmer Biomet | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Artis Q ceiling$8,099
- COREVALVE EVOLUT R$6,159
- MitraClip$1,067
- HawkOne$830
- AMPLATZER AMULET$278
- MitraClip System$264
- GENERAL - STENTS$137
- SAPIEN 3 Ultra RESILIA$123
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$121
- LifeSPARC System$120
- JARDIANCE$118
- GENERAL - THERAPIES$105
How this compares
$25,156 in reported general payments places this provider in the 80th percentile of 65 interventional cardiology providers in Mississippi.
See all interventional cardiology providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 403 | $266,402 |
| EntrestoSacubitril/Valsartan | 195 | $148,186 |
| FarxigaDapagliflozin Propanediol | 108 | $77,166 |
| JardianceEmpagliflozin | 78 | $61,844 |
| BrilintaTicagrelor | 102 | $52,245 |
| XareltoRivaroxaban | 44 | $42,688 |
| Praluent PenAlirocumab | 22 | $21,686 |
| Repatha SureclickEvolocumab | 25 | $16,218 |
| Metoprolol Succinate | 436 | $4,574 |
| Atorvastatin Calcium | 468 | $3,553 |
| Ranolazine ErRanolazine | 40 | $3,518 |
| ClopidogrelClopidogrel Bisulfate | 391 | $2,996 |
| Amiodarone Hcl | 80 | $1,949 |
| Rosuvastatin Calcium | 160 | $1,666 |
| Carvedilol | 346 | $1,659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $513 | $266,402403 claims |
| NovartisEntresto | $1,021 | $148,186195 claims |
| AstraZenecaFarxiga, Brilinta | $106 | $129,411210 claims |
| Boehringer IngelheimJardiance | $473 | $61,84478 claims |
| Johnson & JohnsonXarelto | $77 | $42,68844 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 65 interventional cardiology providers in Mississippi.
Other interventional cardiology in Jackson
- John WinscottJackson$482K
- William CrowderJackson$331K
- James BennettJackson$160K
- Brett BennettJackson$126K
- Alejandro Lemor FerrandJackson$37K
- David YoungJackson$28K
- Richard GuynesJackson$26K
- Catherine LoweJackson$21K
- Jeremy WhiteJackson$18K
- Kellan AshleyJackson$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.